Stocktoria
MACROGENICS INC MGNX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-10-10
MACROGENICS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $149.5M | $150.0M | $58.7M | $151.9M | $77.4M |
| R&D expense | $147.2M | $177.2M | $166.6M | $207.0M | $214.6M |
| Operating income | -$72.8M | -$110.6M | -$168.2M | -$121.4M | -$202.8M |
| Interest expense | — | $1.1M | $1.4M | $0 | $0 |
| Income tax | -$672,000 | $944,000 | $0 | $0 | $0 |
| Net income | -$74.6M | -$67.0M | -$9.1M | -$119.8M | -$202.1M |
| EPS (diluted) | $-1.18 | $-1.07 | $-0.15 | $-1.95 | $-3.37 |
| Operating cash flow | -$81.0M | -$68.4M | -$78.2M | -$87.0M | -$143.8M |
| Free cash flow | -$83.0M | -$72.1M | -$80.0M | -$90.6M | -$150.0M |
| Cash & equivalents | $57.2M | $182.8M | $101.0M | $108.9M | $123.5M |
| Inventory | $7.9M | $0 | $1.2M | $1.5M | $4.4M |
| Total assets | $256.8M | $261.7M | $298.4M | $280.5M | $335.2M |
| Total liabilities | $201.3M | $145.6M | $145.8M | $138.5M | $95.6M |
| Shareholders' equity | $55.6M | $116.1M | $152.6M | $142.0M | $239.6M |
Source: SEC EDGAR filings · CIK 0001125345 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.